Noom Launches Affordable Microdose GLP-1 Program
Slice of Healthcare Team
08/13/2025
Key highlights
- New program starts at $119, includes medication (if prescribed) and Noom GLP-1 Companion.
- Microdose approach minimizes side effects—70% report none.
- Personalized, physician-designed dosing protocol guided by real-world health data.
- Combines GLP-1 medication with Noom’s behavior change platform.
- Available in 45 states with home prescription delivery.
Source: GlobeNewswire
Notable Quotes
“ The Noom Microdose GLP-1Rx Program was designed to address this issue by introducing GLP-1s gradually and sustaining them at a microdose level, as part of a larger holistic behavior change platform. LP-1s are no longer only useful for weight loss and diabetes – they are critical for building metabolic resilience and reducing inflammation. ”
Dr. Jeffrey Egler, Chief Medical Officer at Noom
“ By offering a no-cost way for anyone to build healthy habits with Noom, we can reach millions more Americans with the tools to help them live better longer. ”
Cook, CEO at Noom
Why This Matters
The U.S. obesity rate exceeds 40%, far outpacing other developed nations, while GLP-1 medication costs in the U.S. are up to five times higher. Noom’s Microdose GLP-1Rx Program directly tackles three major barriers to obesity treatment—cost, side effects, and lack of sustainable behavior change. By pairing affordable microdose GLP-1s with a robust behavior change platform, Noom aims to improve adherence, make treatment accessible to more people, and help reverse the nation’s obesity trend. The launch also aligns with Noom’s broader commitment to health equity through a forthcoming free tier for all Americans, underscoring the company’s focus on long-term, whole-person health.
Expert Insights
Share Your Expert Insights
Have relevant experience or professional perspective? Add your thoughtful insights to this article.
